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Two studies involved moderately emetogenic regimens. Pal-
onosetron 0.25mg was associated with a signiﬁcantly higher
complete response (CR) rate in the delayed phase compared to
ondansetron (74.1% vs. 55.1%, p = 0.001) and dolasetron
(54.0% vs. 38.7%, p = 0.004). The CR rate with palonosetron
0.25mg in the acute phase was signiﬁcantly higher than
ondansetron (81.0% vs. 68.6%, p = 0.009), but only numeri-
cally better than dolasetron (63.0% vs. 52.9%, p = 0.049). In
the trial with highly emetogenic agents, CR rates were compa-
rable between palonosetron 0.25 mg and ondansetron in both
the acute (59.2% vs. 57.0%, p = 0.701) and delayed (45.3%
vs. 38.9%, p = 0.180) phases. The FDA considered the CINV
claims relative to placebo due to lack of approval of compara-
tors for delayed CINV. Because of its long half-life, NCCN
guidelines indicated that single-dose palonosetron could be con-
sidered at the start of a multi-day chemotherapy regimen
instead of multiple daily doses of other 5-HT3-RAs; however,
none of the guidelines designated a preferred 5-HT3-RA. CON-
CLUSION: 5-HT3-RAs can be considered clinically inter-
changeable. While palonosetron may provide convenience by
avoiding the need for repeat daily dosing, this needs to be bal-
anced against its additional cost given the advent of generic
5-HT3-RAs.
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OBJECTIVE: Multiple myeloma (MM) is a plasma-cell malig-
nancy with approximately three years median survival. Patients
usually relapse or become refractory to existing treatments. Bort-
ezomib(VELCADE) is indicated for the treatment of MM in
patients who have received at least one prior therapy. The elec-
tronic VELCADE Observational Study (eVOBS) is a multicenter
naturalistic study designed to evaluate the clinical and outcomes
beneﬁts of bortezomib in actual clinical practice. METHODS:
This is a multi-center study with sites in Belgium, France, Greece,
Russia, Spain, Sweden, and Turkey. The study enrollment period
is between October 2006 and December 2008 with a 3-year
follow-up. Adults are eligible for study if they are scheduled to
initiate bortezomib within the approved indication. All bort-
ezomib dosages and concomitant treatments are permitted,
except investigational therapies. Data treatment response, and
safety are collected prospectively. RESULTS: The current analysis
reports data collected on patients initiated with bortezomib
between October 2006 and July 2007. A total of 86 pts with at
least four months of data are included in this analysis. Demo-
graphic and clinical characteristics of the initial participants were
similar to those of the participants in the prospective controlled
phase 3 APEX trial. Adverse events (AEs) were reported in 61
(71%) pts, including Grade 3 AEs in 38% and Grade 4 AEs
in 9%. AEs were treatment-related in 45% of patients and
treatment-limiting in 9%. Presently, 72 of 86 pts have been
evaluated for response, of whom 5 (7%) achieved complete
response, 9 (13%) achieved near complete response, and 30
(42%) achieved partial response. Updated data will be presented
at the meeting. CONCLUSION: In this preliminary analysis of
data from a prospective, observational study, response rates and
safety data demonstrate that bortezomib-containing regimens are
effective and well-tolerated in the treatment of MM in actual
clinical practice and the results are in line with previously pub-
lished studies.
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OBJECTIVES: The Nationwide Inpatient Sample is part of the
Healthcare Cost and Utilization Project, and is the only national
hospital database with charge information on all patients,
regardless of payer, including persons covered by Medicare,
Medicaid, private insurance, and the uninsured. It is the purpose
of this study to examine the relationship between patient out-
comes and conditions of the patients undergoing different treat-
ments for lung cancer. METHODS: There are ﬁfteen possible
patient diagnoses in the dataset. SAS Enterprise Guide was used
to obtain Lung Cancer data from NIS by using the CATX and the
RXMATCH statements in SAS. We bring all ﬁfteen diagnoses
into one column as a string of codes, using the CATX function.
Total charges are used to examine the relationship between diag-
noses and procedures. The generalized linear regression model
was used to ﬁt the data. RESULTS: After ﬁltering down to lung
cancer using the strings of diagnoses, there were 5457 records in
the data set. By the plot method, we selected variables related to
Total charges. We found that the Total charges were highly
related to Age in years at admission, Diagnosis Related Group,
Length of stay and Died during hospitalization. By the basic
criterion, deviance residuals and Pearson chi-square residuals,
the speciﬁed model ﬁts the data reasonably well. From the Type
1 and Type 3 analysis, all the estimates for the intercept, Los,
Age, DRG, and Died were 10.1805, 0.1181, 0.003, -0.0008, and
-1.024, respectively. All of them were statistically signiﬁcant.
Co-morbid diagnoses that increased total charges include coro-
naries, multiple signiﬁcant traumas, and cardiac implant. CON-
CLUSIONS: Our analysis revealed that there was a speciﬁed
relationship between these variables. With increasing of length of
stay, age in years at admission, small codes of diagnosis related
group and surviving during hospitalization, the total charges
increase, which is reasonable.
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OBJECTIVE: Complications from skeletal-related events (SREs)
constitute a challenge to the care of patients with bone metastasis
originated from any type of malignancy. Our objective was to
determine the reduction in morbidity (SREs) and mortality
(overall) of clodronate, pamidronate, and zoledronic acid in
patients diagnosed with bone metastasis. METHODS: Medline
and Embase (from inception to October 2007) were searched in
order to retrieve randomized clinical trials evaluating targeted
bisphosphonates in cancer patients with bone metastasis.
Patients with a deﬁnite (i.e., biopsy-proven) diagnosis of meta-
static bone disease were included in the analysis. We extracted
and combined data from studies describing the number of
patients reporting 12-month SREs and mortality data. Two inde-
pendent reviewers identiﬁed articles, then extracted data; results
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